<div id="readability-page-1"><div><ul><li>Allogene (ALLO) ended its exclusive Overland license for cell therapies in China, Taiwan, South Korea and Singapore on May 12, 2026; no cash paid, equity reduced to ~3%, and governance deal updated.12</li><li>Allogene (ALLO): ALLO-316 earned RMAT; ALLO-329 got three Fast Track designations. Company expanding ALPHA3 global sites and set interim and final analyses dates.3</li><li>Allogene (ALLO) interim ALPHA3 Phase 2: cema-cel showed 58.3% MRD negativity vs 16.7% observation in 24 first‑line LBCL patients; favorable safety profile; expanded community access.45</li><li>Allogene (ALLO) Q1 2026: net loss $42.6M, adjusted EPS -$0.18 (improved YoY). No revenue. Cut R&amp;D/G&amp;A. Completed $187.9M offering, cash runway to 2029. Stock -5.7% Q1, +67.9% YTD.67</li></ul></div></div>

ALLO

SBIO

LABU

IBBQ

Allogene (ALLO) has terminated its exclusive Overland license for cell therapies in several Asian countries, effective May 12, 2026, with no cash payment and equity reduced to approximately 3%. The company reported a 58.3% MRD negativity in its ALPHA3 Phase 2 trial and achieved RMAT designation for ALLO-316. In Q1 2026, Allogene posted a net loss of $42.6M with no revenue, but improved adjusted EPS. The company completed a $187.9M offering, extending its cash runway to 2029, while its stock saw a 5.7% decline in Q1 but a 67.9% increase year-to-date.

TradingView

Allogene Therapeutics

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity